Canada · Delayed Price · Currency is CAD Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of CAD 427.93 billion. The enterprise value is 484.13 billion.
| Market Cap | 427.93B |
| Enterprise Value | 484.13B |
Important Dates
The last earnings date was Tuesday, October 27, 2026.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | Mar 11, 2026 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -2.76% |
| Shares Change (QoQ) | -0.47% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 43.89% |
| Float | 1.84B |
Valuation Ratios
The trailing PE ratio is 43.06 and the forward PE ratio is 16.80.
| PE Ratio | 43.06 |
| Forward PE | 16.80 |
| PS Ratio | 5.25 |
| PB Ratio | 8.02 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 19.25 |
| P/OCF Ratio | 17.40 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.07, with an EV/FCF ratio of 21.78.
| EV / Earnings | 34.00 |
| EV / Sales | 5.97 |
| EV / EBITDA | 14.07 |
| EV / EBIT | 17.58 |
| EV / FCF | 21.78 |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 1.29.
| Current Ratio | 0.88 |
| Quick Ratio | 0.58 |
| Debt / Equity | 1.29 |
| Debt / EBITDA | 1.98 |
| Debt / FCF | 3.09 |
| Interest Coverage | 12.36 |
Financial Efficiency
Return on equity (ROE) is 24.33% and return on invested capital (ROIC) is 19.26%.
| Return on Equity (ROE) | 24.33% |
| Return on Assets (ROA) | 10.86% |
| Return on Invested Capital (ROIC) | 19.26% |
| Return on Capital Employed (ROCE) | 23.04% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 1.08M |
| Profits Per Employee | 189,200 |
| Employee Count | 75,267 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.27 |
Taxes
In the past 12 months, Novartis AG has paid 3.73 billion in taxes.
| Income Tax | 3.73B |
| Effective Tax Rate | 20.80% |
Stock Price Statistics
The stock price has increased by +37.34% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +37.34% |
| 50-Day Moving Average | 29.18 |
| 200-Day Moving Average | 27.94 |
| Relative Strength Index (RSI) | 66.04 |
| Average Volume (20 Days) | 1,007 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novartis AG had revenue of CAD 81.44 billion and earned 14.24 billion in profits. Earnings per share was 0.74.
| Revenue | 81.44B |
| Gross Profit | 61.25B |
| Operating Income | 27.67B |
| Pretax Income | 17.95B |
| Net Income | 14.24B |
| EBITDA | 34.17B |
| EBIT | 27.67B |
| Earnings Per Share (EPS) | 0.74 |
Balance Sheet
The company has 12.60 billion in cash and 68.58 billion in debt, with a net cash position of -55.99 billion.
| Cash & Cash Equivalents | 12.60B |
| Total Debt | 68.58B |
| Net Cash | -55.99B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 53.33B |
| Book Value Per Share | 27.98 |
| Working Capital | -5.36B |
Cash Flow
In the last 12 months, operating cash flow was 24.60 billion and capital expenditures -2.37 billion, giving a free cash flow of 22.23 billion.
| Operating Cash Flow | 24.60B |
| Capital Expenditures | -2.37B |
| Depreciation & Amortization | 6.39B |
| Net Borrowing | 22.63B |
| Free Cash Flow | 22.23B |
| FCF Per Share | n/a |
Margins
Gross margin is 75.21%, with operating and profit margins of 33.98% and 17.49%.
| Gross Margin | 75.21% |
| Operating Margin | 33.98% |
| Pretax Margin | 22.04% |
| Profit Margin | 17.49% |
| EBITDA Margin | 41.95% |
| EBIT Margin | 33.98% |
| FCF Margin | 27.72% |
Dividends & Yields
This stock pays an annual dividend of 0.87, which amounts to a dividend yield of 2.73%.
| Dividend Per Share | 0.87 |
| Dividend Yield | 2.73% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 90.40% |
| FCF Payout Ratio | n/a |
| Buyback Yield | 2.76% |
| Shareholder Yield | 5.49% |
| Earnings Yield | 2.32% |
| FCF Yield | 5.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Novartis AG has an Altman Z-Score of 3.56 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.56 |
| Piotroski F-Score | 5 |